The ribosome is one of the major targets for therapeutic antibiotics; however, the rise in multidrug resistance is a growing threat to the utility of our current arsenal. The orthosomycin antibiotics evernimicin (EVN) and avilamycin (AVI) target the ribosome and do not display cross-resistance with any other classes of antibiotics, suggesting that they bind to a unique site on the ribosome and may therefore represent an avenue for development of new antimicrobial agents. Here we present cryo-EM structures of EVN and AVI in complex with the Escherichia coli ribosome at 3.6-to 3.9-Å resolution. The structures reveal that EVN and AVI bind to a single site on the large subunit that is distinct from other known antibiotic binding sites on the ribosome. Both antibiotics adopt an extended conformation spanning the minor grooves of helices 89 and 91 of the 23S rRNA and interacting with arginine residues of ribosomal protein L16. This binding site overlaps with the elbow region of A-site bound tRNA. Consistent with this finding, single-molecule FRET (smFRET) experiments show that both antibiotics interfere with late steps in the accommodation process, wherein aminoacyl-tRNA enters the peptidyltransferase center of the large ribosomal subunit. These data provide a structural and mechanistic rationale for how these antibiotics inhibit the elongation phase of protein synthesis.
antimicrobial | cryo-EM | everninomicin | rRNA | Ziracin M any clinically used antibiotics target the ribosome to inhibit bacterial growth (1) . X-ray crystallography structures have revealed that the majority of antibiotics that target the large ribosomal subunit bind at or near the peptidyl-transferase center (PTC), the active site for peptide bond formation (1, 2) . The emergence of multidrug resistance in pathogenic bacteria, which has the potential to render our current arsenal of antibiotics obsolete, highlights the need for the development of new antibiotics that target distinct sites on the ribosome. Although structurally uncharacterized, biochemical and resistance studies indicate that one such class of antibiotics is the orthosomycins (3), which includes evernimicin (originally termed everninomicin, and hereafter referred to as EVN) and avilamycin (AVI) (2) .
AVI is produced by Streptomyces virdochromogenes strain Tü57 (4), whereas EVN was identified and isolated from the producer Micromonospora carbonacea (5, 6) . EVN and AVI display excellent antimicrobial activity against Gram-positive bacteria (3), including methicillin-resistant Staphylococcus aureus (7), as well as some Gram-negative bacteria, such as Borrelia burgdorferi (8) . Importantly, strains resistant to EVN and AVI do not display cross-resistance to any other known antimicrobial agents, including ribosome-targeting antibiotics, such as chloramphenicol, tetracycline, or erythromycin (9, 10) .
EVN/AVI resistance in Streptococcus pneumoniae and in the archaeon Halobacterium halobium arises via mutations within helix 89 (H89) and H91 of the 23S rRNA (10) (11) (12) . Resistance to EVN and AVI also occurs via the action of methyltransferases that modify H89 and H91 (13, 14) . Consistently, both EVN/AVI protect nucleotides within H89 and H91 from chemical modification (11, 12) , suggesting that these two rRNA helices comprise at least part of the orthosomycin binding site. Additionally, EVN/AVI resistance has been associated with mutations in Arg-51, Ile-52, and Arg-56 of the ribosomal protein L16 in Enterococcus faecalis, E. faecium, S. pneumoniae, and S. aureus (15) (16) (17) (18) . However, it remains unclear whether these effects are direct consequences of EVN/AVI interacting with L16 or are mediated indirectly via changes in the 23S rRNA, as observed for other ribosomal protein-derived resistance mechanisms (2) .
As expected based on the locations of the reported resistance mutations, both AVI and EVN bind to the ribosomal 50S subunit (19) and inhibit protein synthesis in vivo and in vitro (19, 20) . Subsequent in vitro studies revealed that EVN inhibits IF2-dependent 70S initiation complex formation (11, 21) ; however, the inhibitory effect of EVN is not restricted to translation initiation because toeprinting assays indicate that EVN also inhibits translation elongation (22) . EVN and AVI do not inhibit puromycin reaction (11, 12) and do not compete for binding with antibiotics that target PTC of the ribosome, such as chloramphenicol, linezolid, lincomycin, or
Significance
The ribosome is the protein-synthesizing machine of the cell and is a major target for antibiotics. The increase in multidrug-resistant bacteria has limited the utility of our current arsenal of clinically used antibiotics, highlighting the need for further development of compounds that have distinct binding sites and do not display cross-resistance. Using cryo-electron microscopy, we have visualized the binding site of the orthosomycins evernimicin and avilamycin on the bacterial 70S ribosome. The binding site and mode of interaction of evernimicin and avilamycin are distinct from other ribosome-targeting antibiotics. Together with single-molecule studies, our structures reveal how the orthosomycin antibiotics inhibit protein synthesis by preventing accommodation of the aminoacyl-tRNA at the A site of the ribosome.
clindamycin (19) . Moreover, EVN has no inhibitory effect on the ribosome-dependent GTPase activity of EF-G (21). EVN and AVI are hypothesized to inhibit elongation by preventing tRNA binding to the A site (12, 20) ; however, this model remains to be conclusively demonstrated.
AVI has long been used in animal feed as a growth promoter (Surmax/Maxus; Elanco Animal Health), thereby limiting its clinical usefulness. However, EVN (SCH27899; Ziracin) underwent phase II/III clinical trials before being dropped in 2000 by Schering-Plough because of side effects and poor solubility. Nevertheless, the lack of cross-resistance between AVI/EVN and other clinically used ribosome-targeting antibiotics makes the orthosomycins attractive for further investigation (9, 10) . The total chemical synthesis of EVN (23) and the biosynthesis of novel AVI derivatives with improved solubility (24) provide a good basis for further drug development; however, a structural understanding of how these antibiotics interact with the ribosome is necessary to facilitate rational design of improved orthosomycin derivatives.
Here we present two cryo-EM structures of EVN or AVI in complex with the Escherichia coli 70S ribosome at 3.6-to 3.9-Å resolution. These structures reveal that the conserved heptasaccharide core of both orthosomycins spans across the minor grooves of H89 and H91 of the 23S rRNA, whereas the terminal dichloro-ring interacts with the arginine residues of ribosomal protein L16. The binding positions of EVN and AVI overlap with the elbow region of a tRNA bound in the A site. Consistently, single-molecule FRET (smFRET) imaging of the tRNA selection process demonstrates that EVN and AVI allow initial binding of aminoacyl-tRNA (aa-tRNA) at the A site, but prevent complete accommodation of the incoming aa-tRNA, thus providing a structural explanation of how orthosomycin antibiotics inhibit translation elongation.
Results and Discussion
Cryo-EM Structures of EVN and AVI in Complex with the E. coli 70S Ribosome. To determine the structures of EVN and AVI on the ribosome, we prepared Erm-stalled ribosome complexes (SRCs) as reported (25, 26) . The SRCs were incubated with either 100 μM EVN or AVI, and the complexes were then subjected to singleparticle cryo-EM analysis (Materials and Methods). The resulting cryo-EM reconstructions of the EVN-and AVI-SRC had an average resolution of 3.9 and 3.6 Å, respectively, with local resolution extending to 3.5 Å within the core of the ribosome (Fig. S1 ). Careful analysis of the cryo-EM maps revealed only a single binding site of EVN on the 50S subunit of the 70S ribosome, consistent with previous biochemical studies showing a 1:1 stoichiometry of EVN with the 50S subunit (19) . In contrast to early reports that AVI binds to the 30S subunit (20), we observed only a single AVI binding site on the 50S subunit at the same location as EVN, a result that is consistent with the competition between these two antibiotics for ribosome binding (19) .
AVI has a terminal dichloroisoeverninic acid moiety (ring A) linked to a linear heptasaccharide chain consisting of D-olivose (rings B and C), 2-deoxy-
, the unusual pentose L-lyxose (ring G), and the bicyclic eurekanate (ring H) (ref. 27 ; Fig. 1A ). Similar to AVI, EVN contains a nearly identical core heptasaccharide chain, but, unlike AVI, EVN is branched by a 2-deoxy-β-glycoside nitrosugar (ring A′) attached to ring B, and also contains an additional terminal benzyl moiety (ring I) attached to eurekanate ring H (28) (Fig. 1B) . The presence of distinct electron density corresponding to the additional rings A′ and I of EVN in the cryo-EM map of the EVN-SRC, and absence of the same features in the AVI-SRC map, enabled us to unambiguously orient both AVI and EVN on the ribosome ( Fig. 1 C and D) . Despite the good fit of the refined molecular models to the cryo-EM electron density maps, higher resolution will be required to provide an unambiguous description of the hydrogen-bond interactions of the drugs with the ribosome. Nevertheless, these structures reveal that both drugs adopt elongated conformations on the ribosome, with the heptasaccharide rings B-H of both orthosomycins inserting into the minor grooves of H89 and H91 of the 23S rRNA ( Fig. 1E and Movie S1) and the terminal ring A interacting with ribosomal protein L16 (Fig. 2A) .
Interactions of EVN/AVI with Arginine Residues of L16. The terminal dichloroisoeverninic acid moiety (ring A) of AVI establishes stacking interactions with the side chain of Arg-51 of L16 ( Fig. 2 A and B and Movie S1). In addition, the side chains of Arg-55 and -59 also approach ring A of AVI (Fig. 2B) ; however, the density for these side chains is less well defined. In contrast to AVI, the electron density for the terminal region of EVN is bifurcated (Fig. 1D) , consistent with the presence of the additional 2-deoxy-β-glycoside nitrosugar (ring A′) (Fig. 1B) . Unfortunately, the resolution does not allow unambiguous assignment of ring A and A′ to the bifurcated density. Therefore, our current model is based on the rationale that ring A of EVN occupies the same position as ring A of AVI, and the remaining density is then assigned to the ring A′ (Fig. 2C ). Sequence alignments (Fig.  2D) , as well as comparison with the structures of the B. subtilis 70S ribosome (29) and S. aureus 50S subunit (30) (Fig. S2) Interaction of EVN and AVI with H89 and H91 of the 23S rRNA. Within the limits of the present resolution, we observed no significant difference between the interaction of the conserved heptasaccharide cores of EVN and AVI with H89 and H91 of the 23S rRNA ( Fig. 3  A-D) . The largest interaction surface between the drugs and the ribosome encompasses rings B-F of EVN/AVI and the minor groove of H89, specifically, nucleotides A2468-G2472 and A2478-A2482 (Fig. 3 A-D) , which base pair to form the stem of H89 (Fig. 3E) . Additional interactions were observed between rings G and H of EVN/AVI with the minor groove of H91 (Fig. 3 A-D) formed by nucleotides G2527-U2528 and A2534-G2536 (Fig. 3F ). This interaction pattern is consistent with footprinting data on E. coli, E. feacium, and H. halobium ribosomes showing that EVN protects multiple nucleotides within H89, including A2468, A2469, A2471, A2476, A2478, and A2482, as well as nucleotide A2534 in H91, from chemical modification by dimethyl sulfate (DMS) (11, 13) (Fig. 3 A, E, and F) . Similarly, AVI protects A2482 in H89 and A2534 in H91 from chemical modification by DMS on E. coli 70S ribosomes (12) (Fig. 3 B, E, and F). The terminal benzyl moiety (ring I) of EVN establishes additional interactions with nucleotides within the loop of H91 (Fig. 3 A and C) , which may contribute to the higher potency of EVN compared with AVI.
Resistance to EVN/AVI via 23S rRNA Mutations. A striking correlation exists between the nucleotides that comprise the EVN/AVI binding site observed here and the reported mutations in 23S rRNA that confer resistance to these two drugs (Fig. 3 C-F) . In S. pneumoniae, selection for EVN resistance led to the identification of 23S rRNA mutations A2469C, C2480U (in H89), G2535A, or G2536C (in H91) (ref. 10; Fig. 3 C, E, and F). The G2535A mutation was also subsequently reported to confer EVN resistance in E. faecalis (16) .
The archaeon H. halobium has also been used to select for EVN resistance, producing A2471G/C, A2478C, U2479C, and C2480A/U mutations in H89 and G2527A, U2528A, and G2535A mutations in H91 (11) (Fig. 3 C, E, and F) . In contrast, selection for AVI using H. halobium only led to the identification of mutations within H89, namely, G2470U, A2471G, G2473U, U2479C, and C2480U (12) (Fig. 3 D and E) . The increased frequency of resistance mutations located in H89, as well as the higher resistance conferred by these mutations compared with H91 mutations (11, 12) , emphasizes the importance of the extensive interaction surface between rings B-F of EVN/AVI and nucleotides comprising the minor groove of H89. Because all of the reported mutations are expected to alter basepairing potential, resistance is likely to arise from distortions of the helical geometry of H89 and H91, which thereby reduce the affinity of the drugs for their binding site.
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Resistance to EVN/AVI via Methylation of the 23S rRNA. Analysis of the binding site of EVN and AVI reveals a structural basis for the resistance obtained via posttranslational modifications of nucleotides within H89 and H91 (13, 14) (Fig. 4) . S. virdochromogenes Tü57, the producer of AVI, expresses two methyltransferases, AviRa and AviRb, which confer resistance to EVN/AVI. Whereas AviRb methylates the ribose 2′OH of U2479 within H89 to confer high-level AVI resistance, AviRa methylates the N7 position of G2535 within H91 to confer low-level resistance (14, 31) . Inspection of the EVN/ AVI binding site reveals that a 2′O-methylation of U2479 would lead to a direct clash with ring F of the drug (Fig. 4A) . In contrast, N7-methylation of G2535 appears to neither interfere with the drug binding ( Fig. 4B ) nor disrupt base pairing with U2528, suggesting that methylation at this position indirectly confers resistance by inducing local conformational changes, possibly during ribosome assembly. We note that both AviRa and AviRb are required to obtain full protection against the AVI (31), suggesting that they function in a synergistic manner, similar to the methyltransferases that cause resistance to tylosin (32) . The EVN methyltransferase EmtA, which was identified on a plasmid-borne insertion element in EVN-resistant E. faecium strains (isolated from animals given AVI as a growth promotant), was shown to methylate G2470 of H89 (13) . Although the exact site of the modification has not been identified, we note that methylation of the N2 position of G2470 or the ribose 2′OH would lead to a direct clash with rings D and C, respectively, of EVN/AVI (Fig. 4C) , whereas an N7-methylation would most likely confer resistance indirectly via conformational changes.
Inhibition of IF2 and A-tRNA Accommodation by EVN and AVI. EVN has been reported to inhibit formation of the IF2-dependent 70S initiation complex (70S-IC) (11, 21) . Therefore, we compared the binding sites of EVN/AVI relative to structures of IF2 on the 70S ribosome (33) and 30S subunit (34, 35) . No overlap was observed between EVN/AVI and IF2 on the 70S, with the shortest distance between ring E of EVN/AVI being 2-3 Å away from the linker between domains III and IV of IF2 (Fig. S3) . In contrast, alignment of IF2-30S complex to the AVI/EVN-SRC reveals a slight overlap between EVN/AVI and domain IV of IF2 (Fig. S3) , suggesting that EVN/AVI may interfere with IF2-dependent 70S-IC formation by blocking a transient intermediate state of IF2 that arises upon subunit binding and transition from the 30S-IC to the 70S-IC. EVN and AVI have also been suggested to inhibit translation elongation by interfering with the tRNA binding to the A site of the ribosome (12, 20, 22) . Therefore, we compared the binding position of EVN/AVI relative to the tRNA in the A/T state observed during decoding when the aa-tRNA is bound to the ribosome but still remains in complex with EF-Tu (36, 37) , as well as with the tRNA in the classical A/A state in which the acceptor arm of the aa-tRNA is released from EF-Tu and has accommodated at the PTC on the large ribosomal subunit (38) . These comparisons show that the EVN/AVI binding site does not overlap with aa-tRNA within the A/T state, whereas there is direct clash between rings A-C of EVN/ AVI and nucleotides 51-53 within the stem region of the TΨC-loop (elbow region) of fully accommodated aa-tRNA (Fig. 5A, Fig. S4 , and Movie S1).
To investigate the impact of EVN and AVI on the selection and accommodation of aa-tRNA, we used pre-steady-state smFRET measurements that enable real-time visualization of tRNA motion during EF-Tu-catalyzed delivery of aa-tRNA to surface-immobilized ribosomes (39) (40) (41) (Fig. 5B) . Here, the time evolution of FRET efficiency was monitored at 10 ms per frame time resolution within individual 70S ribosomes bound with (Cy3-s 4 U8)-labeled fMettRNA i Met in the P site upon stopped-flow injection of ternary complex containing EF-Tu, GTP and (LD650-acp 3 U47)-labeled Phe-tRNA Phe (Fig. 5B ). As expected from previous studies (40, 41) , in the absence of the drug, productive FRET events leading to the incorporation of aa-tRNA at the A site evolved from a low (∼0.2) to high (∼0.63) FRET state via the reversible transit of at least one intermediate (∼0.35) FRET configuration, which reflects the A/T state of the A-site tRNA (Fig. 5 B and C) (39, 40) . Consistent with rapid aa-tRNA progression through the selection process, the time delay between the initial observation of low FRET and formation of the stable, high-FRET state, corresponding to the fully accommodated, classically configured A/A-tRNA position, was ∼60 ms (∼16 s −1 ) (Fig. 5 B and C and Fig. S5 ). In the presence of saturating concentrations (20 μM) of EVN or AVI, aa-tRNA progression into the ribosome was strongly and specifically blocked during the transition between the A/T state (∼0.35 FRET) and the fully accommodated A/A state (∼0.63 FRET) (Fig. 5 D and E and Fig. S5 ). To examine the dynamics underlying this inhibition, we visualized the ensemble of observed molecular transitions using transition density plots (42) . In this representation, observed transitions appear as peaks in a 2D histogram of initial and final FRET efficiencies (Fig. 5 F-H) . The peak corresponding to reverse transitions from high to intermediate FRET is significantly enhanced in the presence of both EVN or AVI (arrows in Fig. 5 F-H) , confirming that inhibition was characterized by an exacerbation of the reversible excursions between A/T and accommodated positions that normally accompany proofreading (40) (Fig. S4) . These findings are in agreement with toeprinting experiments demonstrating that 70S ribosomes initiated on the AUG start codon of mRNA do not proceed into the elongation phase of translation when increasing concentrations of EVN or AVI are present (Fig. S6) . Our findings contrast with a previous report (22) in which Evn did not appear to significantly affect the first elongation cycle, but, rather, allowed successive rounds of elongation before inhibition was observed. One possibility for this discrepancy is that the strength of the inhibition of the orthosomycins depends on the nature of the aa-tRNA that is being accommodated.
Conclusion
The cryo-EM structures of EVN-and AVI-SRC reported here reveal that both orthosomycins bind to a single site on the large subunit that is distinct from other known antibiotic binding sites on the ribosome (Fig. S7) , explaining the lack of cross-resistance with other ribosome-targeting antibiotics (9, 10) . The orthosomycin binding site comprises the minor grooves of H89 and H91 of the 23S rRNA, as well as arginine residues of L16 (Fig. 1E) , consistent with available chemical protection and resistance data (Figs. 2-4) (10-18) . The binding position for EVN and AVI provides a structural explanation for how the orthosomycins inhibit IF2-dependent 70S-IC formation (11, 21) -namely, by interfering with the transition from the IF2-30S conformation to the IF2-70S that occurs upon subunit joining (Fig.  S3) . Additionally, our smFRET data demonstrate that both EVN and AVI interfere with the accommodation of aa-tRNA at the A site of the ribosome (Fig. 5 C-H) , consistent with the overlap between EVN/AVI and the elbow region of a fully accommodated A-tRNA (Fig. 5A) . Overall, our study also demonstrates that cryo-EM can be used to determine de novo the binding site of antibiotics on the bacterial ribosome, as was also recently demonstrated for the antiprotozoan drug emetine in complex with the Plasmodium falciparum 80S ribosome (43) .
Materials and Methods
The SRCs were prepared essentially as described (25, 44) . Cryo-EM data collection was performed on the Titan Krios (FEI) 300-kV TEM equipped with a Falcon II direct electron detector. Images of individual ribosome particles were aligned by using Motion Correction software (45) , and then particles were selected automatically by using SIGNATURE (46) . All images were processed by using a frequency-limited refinement protocol that prevents overfitting (47) using the SPIDER software package (48), as described (25, 44) . The final maps were subjected to the program EM-BFACTOR (49) to apply an automatically determined negative B factor for sharpening of the map, and local resolution was calculated by using ResMap (50) . Molecular models were fitted and adjusted by using COOT (51) and refined in Phenix (52) . Model validation was carried out by using the MolProbity server (53) , and the final model statistics are presented in Table S1 . All figures showing atomic models as well as Movie S1 were generated by using PyMOL (Schrödinger). Fig. S1 was generated by using Chimera (54) . The smFRET experiments were performed as described (39) (40) (41) 55) . Further details can be found in SI Materials and Methods. The cryo-EM maps and models for the EVN-and AVI-SRC have been deposited in the EMDatabank (accession nos. EMD-8238 and EMD-8237) and the Protein Data Bank (PDB ID codes 5KCS and 5KCR).
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